BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors

  September 16, 2024

   · 

  6 min read
• Press Releases

  ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

  September 16, 2024

   · 

  2 min read
• Press Releases

  Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

  September 16, 2024

   · 

  6 min read
• Press Releases

  Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

  September 16, 2024

   · 

  7 min read
• Press Releases

  Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 13, 2024

  September 16, 2024

   · 

  1 min read
• Press Releases

  CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 13, 2024

  September 16, 2024

   · 

  3 min read
• Press Releases

  iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

  September 16, 2024

   · 

  10 min read
• Press Releases

  IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

  September 16, 2024

   · 

  7 min read
• Press Releases

  Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

  September 16, 2024

   · 

  16 min read
• Press Releases

  Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

  September 16, 2024

   · 

  9 min read